Compare DigitalOcean Holdings Inc (DOCN) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DigitalOcean Holdings Inc vs Incyte Corporation — how do they compare? DigitalOcean Holdings Inc trades at $134.53 (market cap $14.21B), while Incyte Corporation trades at $120.59 (market cap $24.54B). The key difference: Incyte Corporation is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, DigitalOcean Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DOCN | INCY | |
|---|---|---|
Market Cap | $14.21B | $24.54B |
Sector | Technology | Health |
52-Week High | $181.29 | $129.93 |
52-Week Low | $29.99 | $81.61 |
Enterprise Value | $14.97B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DigitalOcean (DOCN) trades at $129.73, up 4.49% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains a bullish technical outlook with support at $124 and resistance at $135. Revenue growth accelerated to 29% year-over-year in Q2 2026, driven by surging AI-native cloud demand, while maintaining robust 40% adjusted EBITDA margins. Analyst consensus remains strongly positive with a $173.71 price target representing 34% upside potential.
DOCN presents compelling growth exposure to the AI infrastructure boom with accelerating revenue and strong profitability, though elevated valuation multiples (P/E 54.94) and high leverage ($1.49B debt) warrant caution. The company's strategic positioning in AI inference workloads and raised 2026 guidance support continued upside, but investors should monitor competitive pressures and execution risks in the rapidly evolving cloud market.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
